公开(公告)号：US20180086821A1

公开(公告)日：2018-03-29

申请号：US15629123

申请日：2017-06-21

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: C07K16/18 ,  A61K38/00 ,  A61K39/00

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and active fragments, monomers and combinations thereof having one or more of the following characteristics: capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, and active fragments thereof. The invention extends to the use of antibodies and fragments in diagnostic and therapeutic applications, including screening assays.

公开(公告)号：US09701745B2

公开(公告)日：2017-07-11

申请号：US14990325

申请日：2016-01-07

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: C07K16/18 ,  C12Q1/68 ,  A61K38/00 ,  A61K39/00

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

公开(公告)号：US20160333078A1

公开(公告)日：2016-11-17

申请号：US14990325

申请日：2016-01-07

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: C07K16/18 ,  C12Q1/68

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

Abstract translation: 公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 神经调节剂具有以下一个或多个特征：它能够诱导髓鞘再生; 结合神经组织; 促进少突胶质细胞的Ca-信号传导; 并促进神经胶质细胞的细胞增殖。 公开了示例性抗体的氨基酸和DNA序列。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到使用人类抗体，片段，肽衍生物和类似材料，以及它们在诊断和治疗应用中的用途，包括用于发现结合神经系统细胞，特别是少突胶质细胞的其它抗体的筛选测定。

公开(公告)号：US20150299316A1

公开(公告)日：2015-10-22

申请号：US14603553

申请日：2015-01-23

Applicant: Elliott A. Gruskin ,  Arthur E. Warrington ,  Allan J. Bieber ,  Moses Rodriguez ,  Eric Walter Theodore Chojnicki

Inventor： Elliott A. Gruskin ,  Arthur E. Warrington ,  Allan J. Bieber ,  Moses Rodriguez ,  Eric Walter Theodore Chojnicki

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/573

CPC classification number: C07K16/28 ,  A61K31/573 ,  A61K39/39533 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/75 ,  A61K2300/00

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Abstract translation: 公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到人抗体，片段，肽衍生物和类似材料及其在上述治疗应用中的用途以及含有它们的药物组合物的使用，其可以以期望的低剂量施用以治疗涉及脱髓鞘的病症，以及 促进髓鞘再生。

公开(公告)号：US08460665B2

公开(公告)日：2013-06-11

申请号：US10557115

申请日：2004-05-17

Applicant: Elliot A. Gruskin ,  Eric Chojnicki ,  Arthur E. Warrington ,  Allan J. Bieber ,  Moses Rodriguez

Inventor： Elliot A. Gruskin ,  Eric Chojnicki ,  Arthur E. Warrington ,  Allan J. Bieber ,  Moses Rodriguez

IPC: A61K39/395

CPC classification number: C07K16/28 ,  A61K31/573 ,  A61K39/39533 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/75 ,  A61K2300/00

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

公开(公告)号：US08420795B2

公开(公告)日：2013-04-16

申请号：US12845977

申请日：2010-07-29

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: C12N15/13 ,  C12P21/04

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

公开(公告)号：US20100291675A1

公开(公告)日：2010-11-18

申请号：US12738774

申请日：2008-10-17

Applicant: Larry R. Pease ,  Moses Rodriguez

Inventor： Larry R. Pease ,  Moses Rodriguez

IPC: C12N5/071 ,  C07K2/00 ,  C07K7/06

CPC classification number: C07K14/4726

Abstract: Materials and methods for using multivalent molecules (e.g., antibodies) to modulate cellular function. A molecule can be targeted to a particular type of cell, either through direct binding to an epitope on the surface of the cell, or through a linker that recognizes both the multivalent molecule and a marker on the cell surface.

Abstract translation: 使用多价分子（例如抗体）调节细胞功能的材料和方法。 分子可以通过直接结合细胞表面上的表位或通过识别细胞表面上的多价分子和标记物的接头来靶向特定类型的细胞。

公开(公告)号：US07473423B2

公开(公告)日：2009-01-06

申请号：US10010729

申请日：2001-11-13

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: A61K39/395 ,  C07K16/06

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

Abstract translation: 公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 神经调节剂具有以下一个或多个特征：它能够诱导髓鞘再生; 结合神经组织; 用少突胶质细胞促进Ca ++信号传导; 并促进神经胶质细胞的细胞增殖。 公开了示例性抗体的氨基酸和DNA序列。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到使用人类抗体，片段，肽衍生物和类似材料，以及它们在诊断和治疗应用中的用途，包括用于发现结合神经系统细胞，特别是少突胶质细胞的其它抗体的筛选测定。

公开(公告)号：US20050019322A1

公开(公告)日：2005-01-27

申请号：US10776442

申请日：2004-02-10

Applicant: Moses Rodriguez ,  Daren Ure

Inventor： Moses Rodriguez ,  Daren Ure

IPC: G01N33/53 ,  A61K31/785 ,  A61K38/16 ,  A61K39/395 ,  A61P3/00 ,  A61P25/00 ,  C07K16/18 ,  C07K16/44 ,  C12N5/02 ,  C12P21/08 ,  G01N33/577

CPC classification number: C07K16/44 ,  A61K38/02 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/74

Abstract: The present invention provides humanized polyclonal and humanized monoclonal antibodies directed against an epitope on glatiramer acetate, also known as Copolymer 1, Copolymer-1, Cop-1 or Cop. Additionally, the subject invention concerns a pharmaceutical composition comprising an antibody directed against an epitope on glatiramer acetate for the treatment of a disease associated with demyelination of central nervous system axons. Also encompassed by the subject invention is a method of treating a subject suffering from a disease associated with demyelination of central nervous system axons. The subject invention further contains methods of stimulating remyelination of central nervous system axons. In addition, the subject invention provides a method of stimulating proliferation of lymphocytes.

Abstract translation: 本发明提供了针对醋酸格拉醋酸酯（也称为共聚物1，共聚物-1，Cop-1或Cop）上的表位的人源化多克隆和人源化单克隆抗体。 另外，本发明涉及一种药物组合物，其包含针对醋酸格拉司坦上的表位的抗体，用于治疗与中枢神经系统轴突脱髓鞘相关的疾病。 本发明还包括治疗患有与中枢神经系统轴突的脱髓鞘相关的疾病的受试者的方法。 本发明还包含刺激中枢神经系统轴突再髓鞘化的方法。 此外，本发明提供了刺激淋巴细胞增殖的方法。

公开(公告)号：US09260512B2

公开(公告)日：2016-02-16

申请号：US13800117

申请日：2013-03-13

Applicant: Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

Inventor： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

IPC: A61K38/00 ,  C07K16/18

CPC classification number: A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

Abstract: Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and active fragments, monomers and combinations thereof having one or more of the following characteristics: capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, and active fragments thereof. The invention extends to the use of antibodies and fragments in diagnostic and therapeutic applications, including screening assays.

Abstract translation: 公开了抗体，特别是人抗体，其具有治疗脱髓鞘疾病和中枢神经系统疾病的活性。 提供神经调节剂，其包含选自能够结合中枢神经系统结构或细胞的抗体的物质，肽类似物，以及具有一个或多个以下特征的活性片段，单体及其组合：能够 诱导髓鞘再生; 结合神经组织; 用少突胶质细胞促进Ca ++信号传导; 并促进神经胶质细胞的细胞增殖。 公开了示例性抗体的氨基酸和DNA序列。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7，MSI19E5和MSI10E10来治疗脱髓鞘疾病和中枢神经系统疾病的方法，以及 其活性片段。 本发明延伸到在诊断和治疗应用中使用抗体和片段，包括筛选测定。